MNG1126
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.409
- KRAS_SIGNALING_DN+0.251
- SPERMATOGENESIS+0.230
- ALLOGRAFT_REJECTION+0.212
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.062
- KRAS_SIGNALING_UP+0.011
- APICAL_SURFACE+0.010
- COAGULATION+0.000
- INFLAMMATORY_RESPONSE-0.013
- COMPLEMENT-0.060
Top 10 suppressed
- MYC_TARGETS_V2-0.568
- OXIDATIVE_PHOSPHORYLATION-0.492
- MYC_TARGETS_V1-0.487
- UNFOLDED_PROTEIN_RESPONSE-0.485
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.482
- DNA_REPAIR-0.469
- NOTCH_SIGNALING-0.468
- PROTEIN_SECRETION-0.467
- ADIPOGENESIS-0.445
- MITOTIC_SPINDLE-0.408
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG597 | — | — | 0.955 |
| 2 | MNG1131 | — | — | 0.955 |
| 3 | MNG90 | — | — | 0.952 |
| 4 | MDT-AP-1143 | Med | Medulloblastoma | 0.946 |
| 5 | MNG1118 | — | — | 0.946 |
| 6 | MNG436 | — | — | 0.945 |
| 7 | MNG1142 | — | — | 0.944 |
| 8 | SRR1413454 | GTEX | — | 0.941 |
| 9 | MNG1259 | — | — | 0.941 |
| 10 | SRR8942979 | — | — | 0.940 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.409 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.251 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.212 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.062 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.011 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.010 | Temsirolimus | — uncovered |